CIBC Private Wealth Group’s Pacira BioSciences PCRX Stock Holding History

CIBC Private Wealth Group’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$259	Buy	+10	New	+$238	﹤0.01%	3168
2025 Q2	–	Sell	-83	Closed	-$2.18K	–	3251
2025 Q1	$2.18K	Buy	+83	New	+$1.99K	﹤0.01%	2665
2024 Q3	–	Sell	-3,222	Closed	-$66.4K	–	3254
2024 Q2	$66.4K	Sell	3,222 -804	-20%	-$22.9K	﹤0.01%	1563
2024 Q1	$117K	Buy	+4,026	New	+$124K	﹤0.01%	1328
2018 Q3	–	Sell	-19	Closed	-$1K	–	1491
2018 Q2	$1K	Hold	19	–	–	﹤0.01%	1904
2018 Q1	$1K	Hold	19	–	–	﹤0.01%	1871
2017 Q4	$1K	Buy	+19	New	+$753	﹤0.01%	1876

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CIBC Private Wealth Group's PCRX Position: Q4 2025 in Review

CIBC Private Wealth Group opened a new position in Pacira BioSciences (PCRX) in Q4 2025: 10 shares worth $259. The stake represents ﹤0.01% of the portfolio and ranks #3168 among its holdings. This is a return to the name: CIBC Private Wealth Group previously reported a position in PCRX as recently as Q1 2025.

CIBC Private Wealth Group first reported a position in PCRX in Q4 2017 and has held it in 7 quarters since. The position peaked at $117K in Q1 2024. 260 funds tracked by Wall St. Rank hold PCRX as of Q4 2025.

CIBC Private Wealth Group held 10 shares of Pacira BioSciences worth $259 as of Q4 2025.
Pacira BioSciences was a new CIBC Private Wealth Group position in Q4 2025.
Pacira BioSciences made up ﹤0.01% of CIBC Private Wealth Group's portfolio in Q4 2025, its #3168 holding.
CIBC Private Wealth Group first reported a position in Pacira BioSciences in Q4 2017 and has held it in 7 quarters since.
CIBC Private Wealth Group's Pacira BioSciences position peaked at $117K in Q1 2024.
260 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.